SYNAGEVA BIOPHARMA CORP's ticker is GEVA and the CUSIP is 87159A103. A total of 97 filers reported holding SYNAGEVA BIOPHARMA CORP in Q3 2013. The put-call ratio across all filers is 0.10 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2015 | $1,137,242,000 | +15.0% | 11,660,432 | +9.4% | 9.46% | -6.3% |
| Q4 2014 | $989,182,000 | +34.9% | 10,660,432 | 0.0% | 10.10% | +9.3% |
| Q3 2014 | $733,225,000 | -34.4% | 10,660,432 | 0.0% | 9.23% | -32.5% |
| Q2 2014 | $1,117,213,000 | +26.5% | 10,660,432 | +0.1% | 13.68% | +21.9% |
| Q1 2014 | $883,480,000 | +32.9% | 10,648,182 | +3.7% | 11.23% | +19.8% |
| Q4 2013 | $664,880,000 | +2.1% | 10,273,182 | 0.0% | 9.37% | +1.2% |
| Q3 2013 | $651,238,000 | +68.2% | 10,273,182 | +11.4% | 9.26% | +20.9% |
| Q2 2013 | $387,189,000 | – | 9,223,182 | – | 7.66% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Baker Brothers Advisors | 10,660,432 | $989,182,000 | 10.10% |
| BB BIOTECH AG | 1,130,476 | $104,897,000 | 3.40% |
| BLUE JAY CAPITAL MANAGEMENT, LLC | 80,000 | $7,423,000 | 3.31% |
| Opus Point Partners Management, LLC | 20,002 | $1,856,000 | 1.84% |
| COLUMBIA WANGER ASSET MANAGEMENT LLC | 3,847,094 | $356,972,000 | 1.77% |
| SECTORAL ASSET MANAGEMENT INC | 363,884 | $33,765,000 | 1.52% |
| Cormorant Asset Management, LP | 100,000 | $9,279,000 | 1.43% |
| Tekla Capital Management LLC | 223,020 | $20,694,000 | 0.97% |
| Lamond Capital Partners LLC | 15,390 | $1,428,000 | 0.94% |
| Squarepoint Ops LLC | 6,700 | $622,000 | 0.60% |